New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
06:09 EDTVRTX, LULUStocks with implied volatility below IV index mean; LULU VRTX
Stocks with implied volatility below IV index mean; lululemon (LULU) 33, Vertex (VRTX) 112.
News For VRTX;LULU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
06:23 EDTLULUlululemon implied volatility of 61 at upper end of index mean range
November 24, 2015
08:51 EDTLULUExpress American Eagle lululemon business trends strong, says BMO Capital
Subscribe for More Information
05:58 EDTLULUlululemon implied volatility of 62 at upper end of index mean range
November 23, 2015
16:20 EDTLULUOn The Fly: Top stock stories for Monday
The buyers and sellers spent most of the day in a tug-of-war, sending the averages back and forth across the flat line. The market is coming off one of its best weeks of the year and spent the day consolidating its most recent gains. The price of crude acted much like equities, as it too moved back and forth across the flat line and was virtually unchanged in the end. ECONOMIC EVENTS: In the U.S., Markit's flash manufacturing PMI for November fell 1.5 points to 52.6, missing expectations for a 54.0 reading. Existing home sales dropped 3.4% to a 5.36M rate in October, lower than the forecast for a 5.4M rate. The Chicago Fed National Activity Index showed a reading of -0.04, versus the expected +0.05 reading. In Europe, Markit's composite services and manufacturing PMI rose to 54.4 in October from a prior reading of 53.9. That reading marks the euro-area's highest level since May 2011. COMPANY NEWS: The well-telegraphed deal to create the world's largest drugmaker was made official this morning, though shares of both of the merging companies sold off as investors continue to fret that the U.S. government may step in to block the transaction, or at least make it less lucrative due to tax code changes. Pfizer (PFE) announced it will combine with Allergan (AGN) in a stock transaction valued at $363.63 per Allergan share on November 20 in a deal with a total enterprise value of approximately $160B. However, Allergan shares declined $10.74, or 3.56%, to $301.70 following the announcement, while Pfizer dipped 86c, or 2.69%, to $31.32... Alcoa (AA) rose 38c, or 4.37%, to $9.07 after activist investor Elliott Management revealed a 6.4% stake, saying it seeks to engage in a "constructive dialogue" regarding the company's recently announced spinoff plans as well as a number of added opportunities it sees to maximize shareholder value... In other activist investor news, Carl Icahn turned up the heat on AIG (AIG) CEO Peter Hancock, saying his talks with Hancock make it "abundantly clear" that he is not willing to take the steps that Icahn has pushed for, including the suggestion that the insurer break up to shrink below the threshold for systemically important financial institutions. Icahn intends to soon commence a consent solicitation, which may include a proposal to add a new director who would agree in advance to succeed Hancock as CEO if asked by the board to do so. MAJOR MOVERS: Among the notable gainers was Tyson Foods (TSN), which rallied $4.44, or 10.17%, to $48.09 after the meat producer reported better than expected quarterly revenue and gave guidance for fiscal 2016. Also higher was lululemon (LULU), which rose another 7% to $52.77, adding to recent gains, as speculation over a possible takeover by a larger rival, such as Under Armour (UA) or Nike (NKE), persists, fueled by continued media mentions. Among the noteworthy losers was GameStop (GME), which fell $1.64, or 4.18%, to $37.62 after reporting weaker than expected Q3 results. Electronic Arts (EA) also slipped 4.75% to $68.98 after GameStop made comments about its "Star Wars Battlefront" game falling short of expectations so far, though several analysts contended the game retailer's comments should be taken with a grain of salt, cautioning that a shift to digital sales may be playing a role in that apparent softness. INDEXES: The Dow fell 31.13, or 0.17%, to 17,792.68, the Nasdaq lost 2.44, or 0.05%, to 5,102.48, and the S&P 500 slipped 2.58, or 0.12%, to 2,086.59.
13:25 EDTLULULululemon adds to gains as takeover speculation persists
Shares of Lululemon Athletica (LULU) rose in afternoon trading as speculation over a possible takeover by a larger rival persists, fueled by continued media mentions. WHAT'S NEW: On Friday, dealReporter credited a Thursday gain for Lululemon to "unsubstantiated rumors" that Under Armour (UA is seeking to make a $62 per share takeover bid for the yoga apparel maker. DealReporter said that Under Armour may not be the best fit to acquire Lululemon based on differences in branding, marketing and culture, but said that Nike (NKE) would be a better fit to take over the apparel company, since it is in the "right position at the right time" to make such a deal work, contacts told The Fly. WHAT'S NOTABLE: Three days after dealReporter commented on the rumors, the New York Post said today that there was "plenty of chatter" that Lulu and Under Armour were in discussions over a possible deal, noting that the latter company has been "actively seeking" growth in the women's sportswear sector. The Post noted that Bloomberg Gadfly suggested that Nike should be spending $7.5B to acquire Lululemon instead of using that money for a $12B buyback. PRICE ACTION: In afternoon trading, Lululemon rallied 5% to $51.76. Over the past five days, Lululemon is up nearly 15%. Reference Link
08:34 EDTVRTXVertex names Michael J. Parini EVP, chief legal officer
Subscribe for More Information
November 20, 2015
10:34 EDTVRTXVertex approval in Europe to bring gradual uptake, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Vertex Pharmaceuticals must now gain reimbursement in each individual country after the European Union approved Orkambi as expected. The approval will ultimately add around 12,000 homozygous F508del cystic fibrosis patients appropriate for the drug, but uptake will be gradual and dependent on the pace of reimbursement. He reiterates an Overweight rating on Vertex with a $180 price target.
09:36 EDTLULUNike, not Under Armour, should buy lululemon, dealReporter says
Lululemon (LULU) gained 3.6% yesterday, which dealReporter credits to "unsubstantiated rumors" that Under Armour (UA) was planning to make a $62 per share takeover bid. Given the differences in their branding, marketing, and culture, dealReporter said it is not sure such a deal would be a good fit, but added that it believes Nike (NKE) is in the "right position at the right time" to make such an acquisition of lululemon work, contacts tell The Fly.
05:36 EDTVRTXVertex receives EU approval for Orkambi
Subscribe for More Information
November 19, 2015
11:00 EDTLULUlululemon November calls active on renewed takeover speculation
Subscribe for More Information
10:55 EDTLULURumor: lululemon strength attributed to renewed takeover speculation
The Fly, in fulfilling its mission of explaining stock movement, often comes across the many unconfirmed rumors being passed through trading desks and social media platforms. On the occasion that rumors or speculation appear on The Fly's news feed, it should be viewed not as giving credence to the conjecture, rather as simply highlighting its impact on the stock prices of the companies involved.
November 18, 2015
05:41 EDTVRTXVertex receives 2 EU approvals for Kalydeco
Vertex Pharmaceuticals announced that the European Commission has approved expansion of the indication for Kalydeco to include children ages 2 to 5 with cystic fibrosis, or CF, who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene and to include people with CF ages 18 and older who have an R117H mutation. Ivacaftor was previously approved in the European Union, or EU, for use in people with CF ages 6 and older who have one of nine gating mutations. In Europe, approximately 125 children with CF ages 2 to 5 have one of the nine gating mutations included in today's approval and approximately 350 adults with CF have an R117H mutation. Vertex will now begin the country-by-country reimbursement approval processes for each new indication.
November 16, 2015
17:02 EDTLULUPoint72 added to lululemon position, subtracted from Netflix position
Subscribe for More Information
07:16 EDTVRTXHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
November 13, 2015
10:50 EDTLULUOptions with increasing implied volatility
Subscribe for More Information
November 12, 2015
10:50 EDTLULUOptions with increasing implied volatility
Options with increasing implied volatility: FTK MW NLNK MNK GOGO LULU RAD FL

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use